
==== Front
J Perinatol
J Perinatol
Journal of Perinatology
0743-8346
1476-5543
Nature Publishing Group US New York

38698211
1973
10.1038/s41372-024-01973-9
Review Article
The spectrum of pneumonia among intubated neonates in the neonatal intensive care unit
http://orcid.org/0000-0003-2443-2732
Bondarev Dayle J.
http://orcid.org/0000-0002-4588-3412
Ryan Rita M.
http://orcid.org/0000-0002-6812-8970
Mukherjee Devashis Devashis.Mukherjee@uhhospitals.org

grid.67105.35 0000 0001 2164 3847 Division of Neonatology, Department of Pediatrics, Rainbow Babies and Children’s Hospital, Case Western Reserve University School of Medicine, Cleveland, OH USA
2 5 2024
2 5 2024
2024
44 9 12351243
28 2 2023
17 2 2024
15 4 2024
© The Author(s) 2024
2024
https://creativecommons.org/licenses/by/4.0/ Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
We review the pathophysiology, epidemiology, diagnosis, treatment, and prevention of ventilator-associated pneumonia (VAP) in neonates. VAP has been studied primarily in adult ICU patients, although there has been more focus on pediatric and neonatal VAP (neo-VAP) in the last decade. The definition as well as diagnosis of VAP in neonates remains a challenge to date. The neonatal intensivist needs to be familiar with the current diagnostic tools and prevention strategies available to treat and reduce VAP to reduce neonatal morbidity and the emergence of antibiotic resistance. This review also highlights preventive strategies and old and emerging treatments available.

Subject terms

Respiratory tract diseases
Bacterial infection
issue-copyright-statement© Springer Nature America, Inc. 2024
==== Body
pmcIntroduction

Invasive mechanical ventilation (IMV) through an endotracheal tube (ETT) continues to progress and evolve in neonatology. It is still a challenge to avoid ventilator-induced lung injuries (VILI) such as volutrauma, barotrauma, and atelectotrauma, inducing lung remodeling and repair. Despite advances in non-invasive ventilation (NIV), IMV is unavoidable for some neonates. Prolonged IMV can lead to VILI, pulmonary interstitial emphysema (PIE), air leaks, subglottic stenosis, as well as ventilator-associated pneumonia (VAP) [1].

The definition of VAP in the neonatal world remains unclear. The Centers for Disease Control and Prevention (CDC) have defined VAP as pneumonia associated with the use of IMV for at least two consecutive days [2]. The CDC and the National Nosocomial Infections Surveillance (NNIS) criteria both define VAP in infants less than one year old who require invasive mechanical ventilation (IMV) for 48 h, but they do not have definite criteria for newborns or premature neonates. The CDC’s definition for VAP states that IMV for at least 2 consecutive days is required for this diagnosis, along with demonstration of worsening gas exchange and evidence of the radiographic finding of new or worsening pulmonary infiltrate [2]. The current CDC criteria for VAP defined for an infant ≤1 year old must include worsening gas exchange and at least 3 of the following: temperature instability, leukopenia or leukocytosis, cough, new onset purulent sputum, change in character in sputum or increase in respiratory secretions, apnea, increased work of breathing, wheezing, rales or rhonchi and bradycardia or tachycardia (Table 1). VAP is a clinical entity that neonatologists must manage and still needs a proper national definition.Table 1 CDC 2015 criteria for Diagnosing Ventilator- Associated Pneumonia (VAP) in <1 year old infants.

Definition	Signs/Symptoms	Imaging	
Ventilator-associated pneumonia (VAP):

Diagnosis of pneumonia in a patient on mechanical ventilation for >2 consecutive calendar days on the date of event, with the day of ventilator placed on the day of or the day before diagnosis of VAP

	Worsening gas exchange (O2 desaturations, increased FiO2 requirement, or increased ventilator demand) AND at least three of the following:

• Temperature instability

• Leukopenia (≤4000 WBC/mm3) or leukocytosis (≥15,000 WBC/mm3) and left shift (≥10% band forms)

• New onset of purulent sputum or change in the character of sputum, increased respiratory secretions, or increased suctioning requirements

• Apnea or signs of respiratory distress

• Wheezing, rales, or rhonchi

• Cough

• Bradycardia (<100 beats/min) or tachycardia (>170 beats/min)

	Two or more serial chest imaging test results with at least one of the following:

New and persistent

or

Progressive and persistent

 • Infiltrate

 • Consolidation

 • Cavitation

 • Pneumatoceles, in infants ≤1 year old

	
Adapted for NICU patients (Neo-VAP)a	
 Same as above	Increased respiratory support + new chest X-ray findings + 3/5 of the following

• Temperature instability

• Tachy- or bradycardia

• Clinical respiratory distress

• Increased ETT secretions

• Abnormal WBC

	
Adapted from the Centers for Disease Control and Prevention (CDC) [2].

WBC white blood cell, NICU neonatal intensive care unit, ETT endotracheal tube.

asee Fig. 3, adapted from Goerens et al. [5].

The incidence of VAP in the neonatal ICU is dependent on the gestational age (GA) of the population, the presence of high-risk patients (such as patients with bronchopulmonary dysplasia, sedation requirements or a history of multiple intubations) as well as geographic location [3, 4]. In addition, reporting the incidence can be a challenge as the definition of neo-VAP can vary within different institutions. In developed countries, the reported incidence of VAP is between 5.8 and 19.7 episodes per 1000 ventilator days, compared with 37.2 per 1000 ventilator days in developing countries [5]. The variability in this incidence may be attributed to the lack of a clear definition of neonatal VAP (neo-VAP). In addition, although neonatologists at various institutions often use the CDC criteria for infants <1 year of age for the diagnosis of neonatal VAP, some institutions use their own criteria. This may contribute to the difference in incidence among centers.

This review aims to present the scientific literature on neo-VAP, including its pathogenesis, diagnosis, outcomes, preventive strategies, and old and emerging treatments available.

Pathogenesis

Pathogenesis of VAP in neonates is multi-factorial. Figure 1 shows the key innate and adaptive immune mechanisms that prevent upper and lower respiratory tract infections. Neonates are predisposed to nosocomial infections due to their immature immune system [6]. In addition, the skin and mucous membranes of premature neonates are not as effective in preventing infection as full-term neonates due to their increased permeability [7]. Premature neonates have an inadequate reserve of preformed neutrophils to mount an immune response, have immature granulocyte migration and bacterial phagocytosis, and have decreased immunoglobulins, as most transfer of immunoglobulins occurs during the third trimester of pregnancy [8, 9]. Lastly, there is evidence to show that the airway epithelium in preterm neonates is both functionally and structurally altered after preterm birth. There is goblet cell hyperplasia, leading to mucus hypersecretion and further airway obstruction, thickening of the ciliated portion of the epithelium, and increased number of apoptotic cells. Airway obstruction secondary to hypersecretion can decrease airway clearance and increase predisposition to VAP [10].Fig. 1 Mechanisms of airway pathogen clearance in upper and lower respiratory tract.

ROS reactive oxygen species, RNS reactive nitrogen species, AECs alveolar epithelial cells, BECs bronchial epithelial cells, ILCs innate lymphoid cells, DCs dendritic cells, HEV high endothelial venule, BALT bronchus-associated lymphoid tissue, iBALT BAL induced in response to infection. Adapted from Kumar V, Front. Immunol 2020 and Adivitiya et al. Biology (Basel) 2021 [86, 87]. Certain parts of this image have been created with BioRender.com.

Endotracheal intubation impairs the natural defense system of mucus clearance. It connects the lungs with the oropharynx, eliminating the glottis’s natural barrier and allowing easy transfer of oral pathogens into the lower respiratory tract [11]. Duration of IMV is an independent risk factor associated with increased risk of VAP in neonates [12]. The oropharynx and pulmonary airways are colonized by non-pathogenic bacteria, which rarely cause disease. Antibiotic use and critical illness result in an abnormal host environment, leading to loss of normal flora and overgrowth of pathogenic species [13, 14]. These factors combine to predispose premature intubated neonates to acquire lower respiratory tract infections (Table 2).Table 2 Risk Factors for Neo-VAP related to prematurity.

Non-modifiable	Modifiable	
• Premature airway epithelium	• Ventilator days	
• Immature immune system	• Prolonged antibiotic use	
• Increased skin permeability	• Aspiration of gastric contents	

Staphylococcus and Ureaplasma are some of the earliest colonizers of the upper airway tracts, appearing within the first five days of life in preterm mechanically ventilated infants [15]. Other bacterial pathogens which colonize neonatal ETTs include Klebsiella, Streptococcus, and Pseudomonas [15]. A cohort of 71 neonates had tracheal aspirates obtained within seven days of age and grouped into different clusters of either pro-inflammatory state or anti-inflammatory state. The study revealed that while Staphylococcus was the predominant species, Ureaplasma was not detected in the anti-inflammatory samples, suggesting that Ureaplasma may play a role in airway inflammation [16]. Collectively, these findings suggest that Staphylococcus is a common colonizer that serves as a commensal organism, and there are potential organisms that elicit a pro-inflammatory state. The microbiology of the ETT tip in neonates correlates closely with the subglottic area rather than the oropharyngeal area [17]. In summary, no particular organism is predominant in neo-VAP; hence, antimicrobial therapy reflects coverage for most gram-positive and gram-negative organisms.

As the upper respiratory airway tracts are constantly exposed to pathogens (either naturally or from nosocomial sources such as suctioning, infant handling, etc.), innate and adaptive immune defenses work in synchrony to clear the respiratory tract of microbes to enable adequate air exchange (Fig. 1). In preterm neonates, lung injury from prolonged ventilation and physical blockage of the endotracheal tube can inhibit pathogen clearance in the lower airway tract, allowing the proliferation of microbes, inflammation, and infection.

Another possible etiology for VAP is that reflux from the gastric fluid can cause gastric bacteria to transit into the airways [18]. This theory remains controversial as studies in the adult and pediatric populations have not consistently proven that acid-suppression prophylaxis prevents VAP [19–22]. The concept that microorganisms from the gastrointestinal tract can be present in the trachea is corroborated by data presented previously from El Abiad et al. in a single-center study in which there was 71% concordance between the organisms isolated from tracheal and gastric aspirates [22, 23].

Biofilms are structured communities of bacteria enclosed in a polymeric matrix adherent to an inert or living surface [13]. Any medical device or implant is a source of biofilm formation and thus can be a permanent source of infection. Intubation bypasses the upper airway, which decreases upper airway bacterial clearance and allows direct passage to the lower respiratory tract, which helps the ETT to act as a reservoir for biofilm formation [24, 25]. Suctioning the ETT can detach the biofilm from the ETT, which can then migrate towards the lower respiratory tract by the ventilator’s positive pressure. Feldman et al. showed that the secretions and airway access tubing lining the interior distal third of the ETT formed a biofilm [26]. The microflora in the ETT biofilms have shown an abundance of Streptococci in the neonatal ETT biofilms and is significantly related to the onset of VAP and colonization by other nosocomial pathogens such as Pseudomonas aeruginosa [27].

Diagnosis

There is no consensus statement from the American Academy of Pediatrics Section on Neonatal Perinatal Medicine or the Committee on Infectious Diseases on the definition of VAP in neonates. The CDC’s definition of VAP includes both clinical and radiographic findings. It is important to note that the rapid resolution of radiographic findings suggests a non-infectious process, such as atelectasis or congestive heart failure, and is inconsistent with VAP [28]. Frequent chest X-rays can be helpful since a longer course of antibiotics could be avoided when rapid resolution of lung “infiltrates” occurs. Chest radiograph findings can range from focal consolidates to subtle areas of infiltrates (Fig. 2).Fig. 2 Chest radiograph images of neonates diagnosed with ventilator-associated pneumonia based on CDC guidelines.

This radiograph was used to diagnose a ventilator-dependent 5-week-old, 27-week GA male with Klebsiella pneumoniae and Staphylococcus aureus pneumonia. CDC Centers for Disease Control and Prevention, GA gestational age.

Prematurity, longer hospital length of stay, and low birth weight are among the risk factors for VAP identified in the preterm population [12]. Sedation has also been associated with an increased risk of VAP, perhaps due to less ability to take deep sighs or to clear the airways [3]. Although multiple reintubation attempts have been associated with increased VAP incidence, this is likely due to a positive association between a higher number of reintubation attempts, increased IMV days, and lower birth weight, both of which are independently associated with increased VAP incidence [29].

Per CDC guidelines, at least one of the following must be collected to identify the causative organism for VAP: blood culture, pleural fluid, quantitative culture from minimally contaminated lower respiratory tract specimen such as broncho-alveolar lavage (BAL), protected specimen brushing or endotracheal aspirate [2]. In adults, BAL and bronchoscopic brushings are commonly used to collect airway samples to avoid contamination from the upper respiratory tract [30]. However, these techniques must be performed with bronchoscopic video guidance, which can be challenging to perform via the smaller endotracheal tubes and airways of neonates, and, often, appropriately sized equipment is a limiting factor. While tracheal aspirates (TAs) are more easily obtained from neonates, results can yield non-infectious colonizers, leading to unnecessary antibiotic usage, the development of antibiotic resistance, and the emergence of multi-drug resistant (MDR) organisms [31]. Also, evidence shows that TAs growing bacteria do not always represent clinical infection. In a retrospective cohort study in a level IV neonatal intensive care unit (NICU) where TA cultures were obtained in intubated neonates, positive cultures were not significantly associated with clinical, laboratory, or radiographic markers used to screen for infection [32]. Non-bronchoscopic BAL or “deep pulmonary lavage,” which employs blind wedging of the catheter below the carina, is also an option for obtaining samples that is a relatively safe diagnostic tool [33–35]. Although the utility of this technique in neonates is unclear, it has been used in randomized trials [36, 37]. Regardless of the sampling method, distinguishing VAP from colonization can be challenging. A cohort of preterm infants with bronchopulmonary dysplasia (BPD) requiring IMV for 21 days with serial TAs obtained at 72 h, seven days, 14 days, and 21 days of age showed that early bacterial colonization with diverse species is present within the first three days of life [38].

The CDC defines purulent sputum as secretions that contain ≥25 neutrophils and ≤10 squamous epithelial cells per low-power field. If the laboratory cannot provide additional information on quantitative reporting, they suggest direct examination results of “many,” “heavy,” “numerous 4+,” or ≥25 neutrophils per low power field to be interpreted as purulent secretions [26]. Alriyami et al. recommend the collection of TAs before and 24 to 48 h after empiric antibiotic treatment to assess changing microbiological patterns, including a decrease in colony counts or whether a polymicrobial sample shifts to a dominant organism, which is suggestive of resistance [22].

Obtaining a blood culture in the setting of pneumonia is controversial. The multicenter Etiology of Pneumonia in Community (EPIC) study showed that bacteremia was uncommonly detected in pediatric patients with community-acquired pneumonia and concluded that blood culture was low yield but could have utility in patients with parapneumonic effusion and intensive care unit (ICU) admission [39]. No study to date assesses the utility of blood culture in the setting of presumed VAP in preterm neonates. However, due to increased predisposition to infection in preterm neonates and the fact that the presentation of sepsis is similar to VAP in neonates, most neonatologists obtain blood cultures when there is a concern for VAP. Obtaining a blood culture will also allow a shorter antibiotic course if the culture does not detect bacteremia.

In a prospective study of extremely preterm neonates who were diagnosed with VAP using CDC guidelines, the most common pathogenic micro-organisms identified from respiratory secretions were Pseudomonas aeruginosa, Enterobacter spp., and Klebsiella for Gram-negative bacteria, and Staphylococcus aureus and Enterococcus spp. for Gram-positive bacteria [40]. In another study of neonates with a definite diagnosis of VAP (defined using the CDC criteria), 25% were polymicrobial VAP. Clinical features, therapeutic responses, and outcomes did not differ between monomicrobial and polymicrobial VAP in this cohort. Therapeutic response was defined by lack of treatment failure. Treatment failure of VAP included neonates who died from VAP, required antibiotics for more than two weeks, progression to bacteremia, and clinical deterioration after seven days of effective antibiotic treatment [41].

Endotracheal fungal colonization can also be found in 8.3–42% of intubated premature neonates [42]. Anti-fungal coverage should be considered for neonates not responding to antibacterial drugs or if the neonate has hyperglycemia, thrombocytopenia, and signs of skin involvement [43].

Specific biomarkers for pneumonia have been extensively studied in adults and may be helpful in neonates. C-reactive protein (CRP) is a well-studied marker in neonates and is used as a biomarker in sepsis [44]. CRP is a pentraxin protein produced by hepatocytes as an indirect response to inflammation. As tissue damage occurs, cytokine release triggers the hepatocytes to produce CRP that peaks within 4-6 h upon the onset of inflammation [44]. Single-center studies have shown that serum CRP is elevated in the majority of neonates diagnosed with VAP [45, 46]. The BioVAP study is a prospective multicenter observational study that evaluated the utility of CRP and procalcitonin in adults who received mechanical ventilation for >72 h. Their results showed that CRP and its rate of change per day (CRP ratio) were the best predictors of VAP in their patient cohort [47]. In a prospective cross-sectional study among 320 neonates with a cut-off value of 3.6 ng/mL, pooled sensitivity was 78%. At the same time, specificity was 70% in diagnosing neonatal sepsis [48]. Brown et al. performed a meta-analysis of 2 225 infants with sepsis and reported a median specificity of CRP of 74% with a median sensitivity of 62%, concluding that CRP may not be a valuable tool to withhold antibiotics considering an ongoing infection [49]. Both studies reflect that CRP can potentially be used in the correct clinical context of sepsis. Hence, the absence of CRP elevation does not rule out sepsis if the clinical picture suggests otherwise. Perhaps the trend of CRP can be used to guide treatment efficacy. In addition, it is essential to note that these studies are focused on neonatal sepsis as opposed to VAP. No studies have investigated the sensitivity and specificity of CRP in neo-VAP.

Another biomarker that could be utilized to diagnose VAP is procalcitonin (PCT). PCT was initially found to be increased in patients with staphylococcal toxic shock syndrome, and this resulted in numerous studies to assess the utility of PCT as a biomarker for sepsis [50]. PCT is a prohormone secreted as part of the inflammatory response to endotoxins in response to bacterial infection. In bacterial infection, inflammatory cytokines (such as tumor necrosis factor-alpha, IL-1β, and IL-6) induce gene expression responsible for PCT production. Cytokines that are selectively increased in response to viral infection do not cause the same upregulation of PCT compared to specific bacterial cytokine markers [51]. PCT can be used reliably to rule out bacterial infection [52]. In a multicenter randomized controlled trial (NeoPIns), 1 408 neonates were randomized either to PCT-guided decision-based versus standard care-based antibiotic treatment for early-onset sepsis, and the results showed that neonates enrolled under PCT-guided decision-making had a shorter duration of antibiotic use compared to the control group, without increase in any adverse events. Some neonatal and pediatric VAP studies have shown that PCT has an 80–90% sensitivity [53, 54]. A meta-analysis of 39 studies comparing PCT and CRP revealed that the mean sensitivity of early-onset sepsis (EOS), late-onset sepsis (LOS), and both EOS and LOS combined are 73.6%, 88.9%, and 76.5% respectively suggesting that procalcitonin is superior to CRP. However, only four studies included VLBW in their analysis [55]. This poses the same dilemma as CRP as these studies reflect neonatal sepsis, as opposed to neo-VAP. However, PCT may have a role in monitoring ongoing infections.

Presepsin is another potential biomarker/indicator of early-onset sepsis and has been evaluated in the diagnosis of VAP in the adult and pediatric populations. Presepsin is a product of the cleavage of CD14 from bacterial proteases during sepsis [56]. A recent meta-analysis of presepsin utility in diagnosing early-onset neonatal sepsis showed high sensitivity (93%) and specificity (91%), and its accuracy was not affected by the GA of the patients [57]. A cross-sectional observational study performed in intubated neonates from whom TAs were analyzed for presepsin showed that TA presepsin suggested the presence of early-onset pneumonia based on CDC criteria [58]. These studies show some promising utility of presepsin and its association with neo-VAP.

Point-of-care ultrasound is increasingly used for the diagnosis of VAP as an interpretation of radiographs can be challenging in patients with underlying chronic lung disease. When lung ultrasound was studied as a potential diagnostic tool for VAP, it showed a sensitivity of 94% with an area under the curve of 0.97. In this study, neo-VAP was determined by a multi-parameter ventilator-associated pneumonia score adapted from Goerens et al. and respiratory deterioration and confirmed by isolation of pathogenic microorganisms in airway aspirate. The criteria for lung ultrasound findings concerning for neo-VAP include the presence of consolidation ( >0.5 cm), pleural effusion, arborescence, or linear dynamic bronchograms [59].

Outcomes

VAP has been associated with increased healthcare costs. A study by Ratcheva et al. demonstrated that in a cohort of 107 neonates on MV for >48 h, the length of stay for patients who met the criteria for VAP was 32 days compared to 18 days for non-VAP patients. The median hospital cost for patients with VAP is €3675.77, compared to the lower expenses of €2327.78 for non-VAP patients (U = 1791.5, p < 0.001) [60]. In addition to increased healthcare costs, VAP is also associated with higher morbidity and mortality. In a prospective cohort study in the US of 229 patients admitted to the NICU with a birth weight ≤ 2000 grams receiving at least 48 h of IMV, 28.3% met the CDC VAP criteria for infants. The authors demonstrated a significant association between VAP and mortality in neonates who stayed in the NICU for greater than 30 days (RR 8 with 95% CI 1.9–35) [40]. This highlights the importance of monitoring VAP to decrease mortality. A prospective cohort study of 199 inborn neonates who were mechanically ventilated for 48 h was classified as either exposed or unexposed to VAP defined by CDC < 1-year-old criteria. The study revealed that the incidence of BPD was higher in VAP patients with an adjusted relative risk ratio of 3.5 (1.002–12.7, P = 0.049) and the number needed to harm of 2.07. However, the composite outcome of BPD/mortality did not differ. Infants diagnosed with VAP are also smaller in GA and have longer IMV duration, both of which are risk factors for BPD. This emphasizes the importance of hypervigilance with the diagnosis and treatment of neo-VAP in the ELBW population with pre-disposition to BPD. In addition, VAP-exposed neonates had a longer length of stay (87 [43–116] vs 14 [8–52] days, P < 0.0001) as well as fewer ventilator-free days (22 [14–24] vs 11 [5–17.7] days, P = 0.05) compared to non-exposed neonates, which remained statistically significant after adjusting for GA. Respiratory infections, rehospitalization, and home oxygen therapy were similar in VAP and non-VAP cohorts [61]. In another prospective study by Wang et al., neonates with polymicrobial VAP were shown to have a significantly increased incidence of neurological sequelae with an adjusted odds ratio of 2.74 (95% CI 1.18–6.36, P = 0.019) [41].

The emergence of MDR organisms can be a sequela of utilizing broad-spectrum antibiotics to treat VAP in the NICU. Wang et al. reported the incidence of MDR neo-VAP was 39.2%, and these neonates were shown to have a longer duration of antibiotic use and delayed resolution of symptoms [62]. This highlights the importance of identifying microbes involved in VAP to narrow antibiotic coverage to prevent the emergence of MDR organisms. This is one example in which TA cultures can be helpful.

Management

Understanding the microbiology of VAP is essential to making an informed decision on empiric antibiotic treatment, followed by narrowing it down to specific targeted therapy based on microbial sensitivities or discontinuing antibiotics.

Most management data in neo-VAP is focused on neonatal sepsis rather than VAP. In addition, there are no uniform recommendations regarding antibiotic guidance for neo-VAP, and most centers use empiric antibiotic therapy in VAP as they would for early or late-onset neonatal sepsis. Current recommendations are to use ampicillin and gentamicin for early-onset sepsis (within 72 h of birth) and nafcillin and gentamicin for late-onset sepsis [63]. Broad coverage for the source of infection targeting known typical nosocomial flora, antibiotic susceptibilities of previous infections, and antibiogram patterns for each NICU should all be considered. Empiric antibiotics for late-onset infection should cover Staphylococcus species and Gram-negative bacteria such as Pseudomonas aeruginosa, Klebsiella spp, Escherichia coli, and Serratia marcescens. If there is an associated risk of aspiration, anaerobic coverage should also be considered. In infants who do not seem to be improving, a third or fourth-generation cephalosporin (e.g., ceftazidime or cefepime) with pseudomonal coverage is recommended, as well as adding vancomycin for methicillin-resistant staphylococcal coverage. When these higher-level antibiotics are being used, it is prudent to involve pediatric infectious disease specialists with expertise in antimicrobial stewardship to limit antibiotic resistance in the NICU.

Inhaled antibiotics reduce systemic toxicity as they are given locally with limited systemic absorption. Nakwan et al. reported treatment of Acinetobacter baumanii in a small cohort of preterm neonates using aerosolized colistin for 72 h as an adjunct to standard intravenous antibiotic treatment [64]. This was a retrospective matched case-control study in 16 neonates with MDR Gram-negative VAP and showed that neonates who received both intravenous and inhaled colistin had a higher clinical cure and microbial eradication, along with lower ventilator requirements at the end of treatment as compared with neonates receiving intravenous colistin alone [65]. These studies show some clinical evidence for adding an inhaled antibiotic, but a more extensive cohort study is needed to confirm clinical efficacy. However, it is crucial to recognize that inhaled or oral drugs are not typical treatments for neonatal pneumonia in the setting of presumed sepsis. Although it is used in some NICUs, there has not been a large cohort study on inhaled antibiotics in preterm neonates to assess their efficacy and toxicity.

There is no consensus on the duration of treatment of neo-VAP. However, Goerens et al. provided a recommendation for suspected VAP and length of treatment based on clinical status and laboratory findings of (1) worsening clinical and ventilation conditions, (2) abnormal laboratory findings (CRP > 20 mg/l), leukopenia (≤4000 WBC/mm3) or leukocytosis (>15,000 WBC/mm3) and left shift (>10% band forms), (3) and positive cultures from tracheal secretions. If all three criteria are met, the authors recommend a duration greater than or equal to 7–14 days of antibiotic therapy. A treatment of 24–36 h plus an additional 48–72 h would be warranted if the patient only shows 1–2 of the criteria, and discontinuation of antibiotics after 24–36 h if only 0–1 of the criterion is met [5]. Figure 3 shows a modified adaptation from Goerens et al. which can serve as a clinical decision-making tool for the neonatologist at the bedside. It is important to note that this is a proposed algorithm, and data has not been published to assess its efficacy. The clinical rounding team should frequently discuss the duration and choice of antibiotic therapy with the clinical pharmacist. In addition, consulting the pediatric infectious disease team and referring to local antibiogram patterns of each NICU is also warranted. It is worth mentioning that emerging studies show that shorter durations of antibiotics might be as effective as longer durations and can reduce changes in the emergence of antimicrobial resistance [66, 67]. Lewald et al. performed prospective surveillance of infants diagnosed with pneumonia and sterile blood culture receiving a five-day course of antibiotics where 14% of their cohort were infants ≤37 weeks. Their study revealed that only 3% of their cohort had antibiotics restarted after five days for relapsed pneumonia. Three infants died within 14 days of antibiotic discontinuation from Pseudomonas sepsis, and one infant died from Klebsiella sepsis due to necrotizing enterocolitis NEC [68]. The significance of this study is that it shows the potential for shorter course treatment. However, further studies in premature neonates need to be conducted.Fig. 3 Common quality improvement measures and bundles used in neonatal intensive care units to prevent VAP.

The four studies on the periphery depict the most commonly cited studies on the effectiveness of VAP bundles. In the center, we list the measures widely used by NICUs as a part of VAP bundles [73–76].

Prevention

Prevention of VAP is accomplished by avoiding prolonged IMV. Removing the ETT when possible is critical in preventing VAP and should be a focus of everyday clinical decision-making. The CDC and Healthcare Infection Control Practices Advisory Committee (HICPAC) recommends using orotracheal tubes and changing respiratory circuits only for malfunction or contamination. There is no recommendation for routine exchange of ETTs or circuits without any clinical indication [69].

Hand hygiene is an important strategy to prevent nosocomial infections such as VAP. In a study in which alcohol-based hand gels were used for hand hygiene, a reduction of neo-VAP was shown in VLBW neonates [70]. In another study of NICU patients, increased compliance with hand hygiene reduced the incidence of respiratory infections from 3.35 to 1.06 per 1000 patient days [71]. Suctioning of the endotracheal tube is done to clear airway secretions. No specific recommendations on types or frequency of airway suctioning have been shown to decrease the incidence of neo-VAP for neonates. Cordero et al. have shown no difference between open and closed suctioning in neonates regarding VAP incidence or mortality, even though it seems logical that a closed system should be helpful [72].

Studies on VAP in neonates focusing on prevention are limited to quality improvement projects and generally focus on implementing multiple-item bundles (Fig. 4). Azab et al. performed a prospective observational cohort study of 143 neonates, implementing a bundle that included frequent assessment for extubation readiness, hand hygiene, oral hygiene, positioning, closed sterile suctioning, strict reintubation guidelines, and changing the ventilator circuit every seven days. Their bundle showed a significantly decreased incidence of neo-VAP from 36.4 to 23 cases per 1000 IMV days (P = 0.0006) [73]. Jacobs Pepin et al. enforced a similar NICU bundle with the addition of guidelines on disinfecting the patient environment and draining condensation from ventilator tubing when suctioning and showed a decrease in the incidence of neo-VAP from 8.5 to 2.5 cases per 1000 ventilator days (P < 0.004) [74]. Ceballos et al. demonstrated that in addition to the common interventions for the prevention of hospital-acquired infection in the NICU, replacing the circuit with reintubation, ensuring a sterile field upon intubation, frequent endotracheal tube positioning, a protocol for weaning off the ventilator decreased their incidence of neo-VAP from 8.9 to 3.9 cases per 1000 vent days in neonates <750 g [75]. Lastly, a prospective cohort study by Pinilla-Gonzales et al. introducing a similar bundle with the addition of sterile airway management and feeds running for 60–120 min as opposed to bolus or continuous feeds showed a decrease of VAP incidence from 11.7 to 1.9 cases per 1000 ventilator days (P < 0.01) [76].Fig. 4 Bedside algorithm for the diagnosis and treatment of neonatal VAP.

Flowsheet for the neonatal provider at the bedside to aid in diagnosing and managing VAP in the neonate based on CDC guidelines and published studies and modified from Goerens et al. Front Pediatr 2018 [5].

Elevating the head of the bed is a part of some neo-VAP prevention bundles. This originated from adult literature proposing that VAP is associated with supine patient positioning, which promotes gastroesophageal reflux with subsequent aspiration. Gastric content refluxing into the airway is believed to increase the risk of VAP, as gastrointestinal pathogens can colonize the airway. However, head of bed elevation is against safe sleep recommendations by the American Academy of Pediatrics. Bagucka et al. showed that head-of-bed elevation can promote reflux in term infants compared with supine positioning [77, 78]. In the pediatric literature, there is no significant difference in VAP incidence between patients who receive H2-blocker prophylaxis compared to patients who did not [79]. In addition, the use of histamine H2-receptor antagonists (H2-blockers, e.g., ranitidine) in neonates is controversial since recent studies have shown that the use of H2-blockers could be associated with NEC, sepsis, osteoporosis, and intraventricular hemorrhage [80].

Several other VAP preventive measures include using bacteriostatic nanotechnology-coated ETTs and probiotics. In adults, bacteriostatic nanotechnology coating can be used on the ETT to prevent biofilm formation. However, this has not been studied in the neonatal population, and efforts are underway to adapt this technology potentially [81]. Sun et al. performed a systematic review and meta-analysis in adults, children, and neonates on the efficacy and safety of probiotics in preventing VAP. It showed evidence to suggest that prophylactic probiotics could help prevent VAP [82]. In one large Level IV NICU, placement of ultra-violet germicidal irradiation into the heating-ventilation-air conditioning circuit significantly decreased the VAP rate [83]. There is also evidence that oropharyngeal colostrum could significantly reduce VAP and NEC [84]. Lastly, there is emerging evidence for using nebulized hypertonic saline for airway clearance. A small cohort study in premature infants showed that nebulized hypertonic saline decreases VAP occurrence [85].

Conclusion

Neo-VAP is a challenging diagnosis given the current CDC definitions that are not specific to neonates, especially preterm neonates, who constitute most of the neo-VAP burden. The diagnosis and management of VAP have progressed minimally over the last decade despite medical and technological advancements in neonatology. There are few sensitive or specific markers for diagnosing pulmonary infection in neonates apart from culture, which has the challenge of separating invasive infection from colonization. Newer biomarkers such as procalcitonin and presepsin have been described but not proven superior to ETT culture. Differentiating colonization and infection presents a significant challenge for neonatologists in a baby with persistent radiographic infiltrates. It often leads to overuse of antibiotics, leading to the emergence of further antibiotic-resistant strains. There is a growing repertoire of VAP prevention bundles and emerging non-antibiotic prophylactic medications. However, there is still a need for better, earlier, and more definitive diagnoses, treatment, and prevention options for neo-VAP, given the associations with increased morbidity and mortality, as well as the contribution to increased length of stay and healthcare costs.

Competing interests

The authors declare no competing interests.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
==== Refs
References

1. Miller JD Carlo WA Pulmonary complications of mechanical ventilation in neonates Clin Perinatol 2008 35 273 81 10.1016/j.clp.2007.11.004 18280886
Miller JD, Carlo WA. Pulmonary complications of mechanical ventilation in neonates. Clin Perinatol. 2008;35:273–81. x-xi18280886 10.1016/j.clp.2007.11.004
2. Pneumonia (Ventilator-associated [VAP] and non-ventilator-associated Pneumonia [PNEU]) Event. 2023.
3. Thatrimontrichai A Rujeerapaiboon N Janjindamai W Dissaneevate S Maneenil G Kritsaneepaiboon S Outcomes and risk factors of ventilator-associated pneumonia in neonates World J Pediatr 2017 13 328 34 10.1007/s12519-017-0010-0 28120236
Thatrimontrichai A, Rujeerapaiboon N, Janjindamai W, Dissaneevate S, Maneenil G, Kritsaneepaiboon S, et al. Outcomes and risk factors of ventilator-associated pneumonia in neonates. World J Pediatr. 2017;13:328–34.28120236 10.1007/s12519-017-0010-0
4. Cernada M Brugada M Golombek S Vento M Ventilator-associated pneumonia in neonatal patients: an update Neonatology 2014 105 98 107 10.1159/000355539 24296586
Cernada M, Brugada M, Golombek S, Vento M. Ventilator-associated pneumonia in neonatal patients: an update. Neonatology. 2014;105:98–107.24296586 10.1159/000355539
5. Goerens A Lehnick D Buttcher M Daetwyler K Fontana M Genet P Neonatal ventilator associated pneumonia: a quality improvement initiative focusing on antimicrobial stewardship Front Pediatr 2018 6 262 10.3389/fped.2018.00262 30320046
Goerens A, Lehnick D, Buttcher M, Daetwyler K, Fontana M, Genet P, et al. Neonatal ventilator associated pneumonia: a quality improvement initiative focusing on antimicrobial stewardship. Front Pediatr. 2018;6:262.30320046 10.3389/fped.2018.00262
6. Donowitz LG Nosocomial infection in neonatal intensive care units Am J Infect Control 1989 17 250 7 10.1016/0196-6553(89)90171-5 2683884
Donowitz LG. Nosocomial infection in neonatal intensive care units. Am J Infect Control. 1989;17:250–7.2683884 10.1016/0196-6553(89)90171-5
7. Harpin VA Rutter N Barrier properties of the newborn infant’s skin J Pediatr 1983 102 419 25 10.1016/S0022-3476(83)80669-6 6827416
Harpin VA, Rutter N. Barrier properties of the newborn infant’s skin. J Pediatr. 1983;102:419–25.6827416 10.1016/S0022-3476(83)80669-6
8. Carr R Modi N Haemopoietic colony stimulating factors for preterm neonates Arch Dis Child Fetal Neonatal Ed 1997 76 F128 33 10.1136/fn.76.2.F128 9135294
Carr R, Modi N. Haemopoietic colony stimulating factors for preterm neonates. Arch Dis Child Fetal Neonatal Ed. 1997;76:F128–33.9135294 10.1136/fn.76.2.F128
9. Kohler PF Farr RS Elevation of cord over maternal IgG immunoglobulin: evidence for an active placental IgG transport Nature 1966 210 1070 1 10.1038/2101070a0 5950290
Kohler PF, Farr RS. Elevation of cord over maternal IgG immunoglobulin: evidence for an active placental IgG transport. Nature. 1966;210:1070–1.5950290 10.1038/2101070a0
10. Looi K Evans DJ Garratt LW Ang S Hillas JK Kicic A Preterm birth: born too soon for the developing airway epithelium? Paediatr Respir Rev 2019 31 82 8 31103368
Looi K, Evans DJ, Garratt LW, Ang S, Hillas JK, Kicic A, et al. Preterm birth: born too soon for the developing airway epithelium? Paediatr Respir Rev. 2019;31:82–8.31103368
11. Berdal JE Bjornholt J Blomfeldt A Smith-Erichsen N Bukholm G Patterns and dynamics of airway colonisation in mechanically-ventilated patients Clin Microbiol Infect 2007 13 476 80 10.1111/j.1469-0691.2006.01678.x 17430338
Berdal JE, Bjornholt J, Blomfeldt A, Smith-Erichsen N, Bukholm G. Patterns and dynamics of airway colonisation in mechanically-ventilated patients. Clin Microbiol Infect. 2007;13:476–80.17430338 10.1111/j.1469-0691.2006.01678.x
12. Tan B Zhang F Zhang X Huang YL Gao YS Liu X Risk factors for ventilator-associated pneumonia in the neonatal intensive care unit: a meta-analysis of observational studies Eur J Pediatr 2014 173 427 34 10.1007/s00431-014-2278-6 24522325
Tan B, Zhang F, Zhang X, Huang YL, Gao YS, Liu X, et al. Risk factors for ventilator-associated pneumonia in the neonatal intensive care unit: a meta-analysis of observational studies. Eur J Pediatr. 2014;173:427–34.24522325 10.1007/s00431-014-2278-6
13. Oami T Chihade DB Coopersmith CM The microbiome and nutrition in critical illness Curr Opin Crit Care 2019 25 145 9 10.1097/MCC.0000000000000582 30855323
Oami T, Chihade DB, Coopersmith CM. The microbiome and nutrition in critical illness. Curr Opin Crit Care. 2019;25:145–9.30855323 10.1097/MCC.0000000000000582
14. Martin-Loeches I Dickson R Torres A Hanberger H Lipman J Antonelli M The importance of airway and lung microbiome in the critically ill Crit Care 2020 24 537 10.1186/s13054-020-03219-4 32867808
Martin-Loeches I, Dickson R, Torres A, Hanberger H, Lipman J, Antonelli M, et al. The importance of airway and lung microbiome in the critically ill. Crit Care. 2020;24:537.32867808 10.1186/s13054-020-03219-4
15. Li H Song C Liu D Ai Q Yu J Molecular analysis of biofilms on the surface of neonatal endotracheal tubes based on 16S rRNA PCR-DGGE and species-specific PCR Int J Clin Exp Med 2015 8 11075 84 26379907
Li H, Song C, Liu D, Ai Q, Yu J. Molecular analysis of biofilms on the surface of neonatal endotracheal tubes based on 16S rRNA PCR-DGGE and species-specific PCR. Int J Clin Exp Med. 2015;8:11075–84.26379907
16. Wagner BD Sontag MK Harris JK Miller JI Morrow L Robertson CE Prenatal complications are associated with the postnatal airway host response and microbiota in intubated preterm infants J Matern Fetal Neonatal Med 2019 32 1499 506 10.1080/14767058.2017.1407310 29157044
Wagner BD, Sontag MK, Harris JK, Miller JI, Morrow L, Robertson CE, et al. Prenatal complications are associated with the postnatal airway host response and microbiota in intubated preterm infants. J Matern Fetal Neonatal Med. 2019;32:1499–506.29157044 10.1080/14767058.2017.1407310
17. Friedland DR Rothschild MA Delgado M Isenberg H Holzman I Bacterial colonization of endotracheal tubes in intubated neonates Arch Otolaryngol Head Neck Surg 2001 127 525 8 10.1001/archotol.127.5.525 11346427
Friedland DR, Rothschild MA, Delgado M, Isenberg H, Holzman I. Bacterial colonization of endotracheal tubes in intubated neonates. Arch Otolaryngol Head Neck Surg. 2001;127:525–8.11346427 10.1001/archotol.127.5.525
18. Farhath S Aghai ZH Nakhla T Saslow J He Z Soundar S Pepsin, a reliable marker of gastric aspiration, is frequently detected in tracheal aspirates from premature ventilated neonates: relationship with feeding and methylxanthine therapy J Pediatr Gastroenterol Nutr 2006 43 336 41 10.1097/01.mpg.0000232015.56155.03 16954956
Farhath S, Aghai ZH, Nakhla T, Saslow J, He Z, Soundar S, et al. Pepsin, a reliable marker of gastric aspiration, is frequently detected in tracheal aspirates from premature ventilated neonates: relationship with feeding and methylxanthine therapy. J Pediatr Gastroenterol Nutr. 2006;43:336–41.16954956 10.1097/01.mpg.0000232015.56155.03
19. Lopriore E Markhorst DG Gemke RJ Ventilator-associated pneumonia and upper airway colonisation with Gram negative bacilli: the role of stress ulcer prophylaxis in children Intensive Care Med 2002 28 763 7 10.1007/s00134-002-1289-3 12107684
Lopriore E, Markhorst DG, Gemke RJ. Ventilator-associated pneumonia and upper airway colonisation with Gram negative bacilli: the role of stress ulcer prophylaxis in children. Intensive Care Med. 2002;28:763–7.12107684 10.1007/s00134-002-1289-3
20. Albert BD Zurakowski D Bechard LJ Priebe GP Duggan CP Heyland DK Enteral Nutrition and Acid-Suppressive Therapy in the PICU: Impact on the Risk of Ventilator-Associated Pneumonia Pediatr Crit Care Med 2016 17 924 9 10.1097/PCC.0000000000000915 27509362
Albert BD, Zurakowski D, Bechard LJ, Priebe GP, Duggan CP, Heyland DK, et al. Enteral Nutrition and Acid-Suppressive Therapy in the PICU: Impact on the Risk of Ventilator-Associated Pneumonia. Pediatr Crit Care Med. 2016;17:924–9.27509362 10.1097/PCC.0000000000000915
21. Rouze A Jaillette E Nseir S Relationship between microaspiration of gastric contents and ventilator-associated pneumonia Ann Transl Med 2018 6 428 10.21037/atm.2018.07.36 30581836
Rouze A, Jaillette E, Nseir S. Relationship between microaspiration of gastric contents and ventilator-associated pneumonia. Ann Transl Med. 2018;6:428.30581836 10.21037/atm.2018.07.36
22. Alriyami A Kiger JR Hooven TA Ventilator-Associated Pneumonia in the Neonatal Intensive Care Unit Neoreviews 2022 23 e448 e61 10.1542/neo.23-7-e448 35773508
Alriyami A, Kiger JR, Hooven TA. Ventilator-Associated Pneumonia in the Neonatal Intensive Care Unit. Neoreviews. 2022;23:e448–e61.35773508 10.1542/neo.23-7-e448
23. El Abiad MT RA, Nader N, Yu W, Lakshminrusimha S, Kumar VH, Blessing-Hanagan K, et al. Tracheal pepsin activity in intubated very low birth weight (VLBW) infants. Pediatric Acad Soc 2006.
24. Prescott HC, O’Brien JM. Prevention of ventilator-associated pneumonia in adults. F1000 Med Rep. 2010;2:15.
25. Garland JS Strategies to prevent ventilator-associated pneumonia in neonates Clin Perinatol 2010 37 629 43 10.1016/j.clp.2010.05.003 20813275
Garland JS. Strategies to prevent ventilator-associated pneumonia in neonates. Clin Perinatol. 2010;37:629–43.20813275 10.1016/j.clp.2010.05.003
26. Feldman C Kassel M Cantrell J Kaka S Morar R Goolam Mahomed A The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation Eur Respir J 1999 13 546 51 10.1183/09031936.99.13354699 10232424
Feldman C, Kassel M, Cantrell J, Kaka S, Morar R, Goolam Mahomed A, et al. The presence and sequence of endotracheal tube colonization in patients undergoing mechanical ventilation. Eur Respir J. 1999;13:546–51.10232424 10.1183/09031936.99.13354699
27. Pan Y Song S Tang X Ai Q Zhu D Liu Z Streptococcus sp. in neonatal endotracheal tube biofilms is associated with ventilator-associated pneumonia and enhanced biofilm formation of Pseudomonas aeruginosa PAO1 Sci Rep. 2017 7 3423 10.1038/s41598-017-03656-2 28611429
Pan Y, Song S, Tang X, Ai Q, Zhu D, Liu Z, et al. Streptococcus sp. in neonatal endotracheal tube biofilms is associated with ventilator-associated pneumonia and enhanced biofilm formation of Pseudomonas aeruginosa PAO1. Sci Rep. 2017;7:3423.28611429 10.1038/s41598-017-03656-2
28. Ventilator-Associated Event (VAE). National Healthcare Safety Network, Centers for Disease Control and Prevention.
29. Tripathi S MG, Jain A, Kohli N. Study of ventilator associated pneumonia in neonatal intensive care unit: characteristics, risk factors and outcome. Internet J Med Update-EJOURNAL. 2010;5:12–19.
30. Morris AC Kefala K Simpson AJ Wilkinson TS Everingham K Kerslake D Evaluation of the effect of diagnostic methodology on the reported incidence of ventilator-associated pneumonia Thorax 2009 64 516 22 10.1136/thx.2008.110239 19213771
Morris AC, Kefala K, Simpson AJ, Wilkinson TS, Everingham K, Kerslake D, et al. Evaluation of the effect of diagnostic methodology on the reported incidence of ventilator-associated pneumonia. Thorax. 2009;64:516–22.19213771 10.1136/thx.2008.110239
31. Dancer SJ Coyne M Robertson C Thomson A Guleri A Alcock S Antibiotic use is associated with resistance of environmental organisms in a teaching hospital J Hosp Infect 2006 62 200 6 10.1016/j.jhin.2005.06.033 16324769
Dancer SJ, Coyne M, Robertson C, Thomson A, Guleri A, Alcock S. Antibiotic use is associated with resistance of environmental organisms in a teaching hospital. J Hosp Infect. 2006;62:200–6.16324769 10.1016/j.jhin.2005.06.033
32. Langston SJ Pithia N Sim MS Garg M de St Maurice A Chu A Lack of utility of tracheal aspirates in the management of suspected pneumonia in intubated neonates Infect Control Hosp Epidemiol 2020 41 660 5 10.1017/ice.2020.57 32209148
Langston SJ, Pithia N, Sim MS, Garg M, de St Maurice A, Chu A. Lack of utility of tracheal aspirates in the management of suspected pneumonia in intubated neonates. Infect Control Hosp Epidemiol. 2020;41:660–5.32209148 10.1017/ice.2020.57
33. Cernada M Aguar M Brugada M Gutierrez A Lopez JL Castell M Ventilator-associated pneumonia in newborn infants diagnosed with an invasive bronchoalveolar lavage technique: a prospective observational study Pediatr Crit Care Med 2013 14 55 61 10.1097/PCC.0b013e318253ca31 22791095
Cernada M, Aguar M, Brugada M, Gutierrez A, Lopez JL, Castell M, et al. Ventilator-associated pneumonia in newborn infants diagnosed with an invasive bronchoalveolar lavage technique: a prospective observational study. Pediatr Crit Care Med. 2013;14:55–61.22791095 10.1097/PCC.0b013e318253ca31
34. Liao CC Tsai MH Lai SH Lai MY Chu SM Huang HR Safety and clinical application of nonbronchoscopic bronchoalveolar lavage in preterm neonates with clinical ventilator-associated pneumonia Pediatr Neonatol 2021 62 195 201 10.1016/j.pedneo.2020.11.008 33413988
Liao CC, Tsai MH, Lai SH, Lai MY, Chu SM, Huang HR, et al. Safety and clinical application of nonbronchoscopic bronchoalveolar lavage in preterm neonates with clinical ventilator-associated pneumonia. Pediatr Neonatol. 2021;62:195–201.33413988 10.1016/j.pedneo.2020.11.008
35. Dell’Orto V Bourgeois-Nicolaos N Rouard C Romain O Shankar-Aguilera S Doucet-Populaire F Cell Count Analysis from Nonbronchoscopic Bronchoalveolar Lavage in Preterm Infants J Pediatr 2018 200 30 7.e2 10.1016/j.jpeds.2018.04.074 29793870
Dell’Orto V, Bourgeois-Nicolaos N, Rouard C, Romain O, Shankar-Aguilera S, Doucet-Populaire F, et al. Cell Count Analysis from Nonbronchoscopic Bronchoalveolar Lavage in Preterm Infants. J Pediatr. 2018;200:30–7.e2.29793870 10.1016/j.jpeds.2018.04.074
36. D’Angio CT Maniscalco WM Ryan RM Avissar NE Basavegowda K Sinkin RA Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone Biol Neonate 1999 76 266 73 10.1159/000014168 10516393
D’Angio CT, Maniscalco WM, Ryan RM, Avissar NE, Basavegowda K, Sinkin RA. Vascular endothelial growth factor in pulmonary lavage fluid from premature infants: effects of age and postnatal dexamethasone. Biol Neonate. 1999;76:266–73.10516393 10.1159/000014168
37. LoMonaco MB Barber CM Sinkin RA Differential cytokine mRNA expression by neonatal pulmonary cells Pediatr Res 1996 39 248 52 10.1203/00006450-199602000-00010 8825795
LoMonaco MB, Barber CM, Sinkin RA. Differential cytokine mRNA expression by neonatal pulmonary cells. Pediatr Res. 1996;39:248–52.8825795 10.1203/00006450-199602000-00010
38. Mourani PM Harris JK Sontag MK Robertson CE Abman SH Molecular identification of bacteria in tracheal aspirate fluid from mechanically ventilated preterm infants PLoS One 2011 6 e25959 10.1371/journal.pone.0025959 22016793
Mourani PM, Harris JK, Sontag MK, Robertson CE, Abman SH. Molecular identification of bacteria in tracheal aspirate fluid from mechanically ventilated preterm infants. PLoS One. 2011;6:e25959.22016793 10.1371/journal.pone.0025959
39. Fritz CQ, Edwards KM, Self WH, Grijalva CG, Zhu Y, Arnold SR, et al. Prevalence, risk factors, and outcomes of bacteremic pneumonia in children. Pediatrics. 2019;144.e20183090
40. Apisarnthanarak A Holzmann-Pazgal G Hamvas A Olsen MA Fraser VJ Ventilator-associated pneumonia in extremely preterm neonates in a neonatal intensive care unit: characteristics, risk factors, and outcomes Pediatrics 2003 112 1283 9 10.1542/peds.112.6.1283 14654598
Apisarnthanarak A, Holzmann-Pazgal G, Hamvas A, Olsen MA, Fraser VJ. Ventilator-associated pneumonia in extremely preterm neonates in a neonatal intensive care unit: characteristics, risk factors, and outcomes. Pediatrics. 2003;112:1283–9.14654598 10.1542/peds.112.6.1283
41. Wang HC Tsai MH Chu SM Liao CC Lai MY Huang HR Clinical characteristics and outcomes of neonates with polymicrobial ventilator-associated pneumonia in the intensive care unit BMC Infect Dis 2021 21 965 10.1186/s12879-021-06673-9 34535089
Wang HC, Tsai MH, Chu SM, Liao CC, Lai MY, Huang HR, et al. Clinical characteristics and outcomes of neonates with polymicrobial ventilator-associated pneumonia in the intensive care unit. BMC Infect Dis. 2021;21:965.34535089 10.1186/s12879-021-06673-9
42. Kaufman D Fairchild KD Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants Clin Microbiol Rev 2004 17 638 80 10.1128/CMR.17.3.638-680.2004 15258097
Kaufman D, Fairchild KD. Clinical microbiology of bacterial and fungal sepsis in very-low-birth-weight infants. Clin Microbiol Rev. 2004;17:638–80.15258097 10.1128/CMR.17.3.638-680.2004
43. Pradeepkumar VK Rajadurai VS Tan KW Congenital candidiasis: varied presentations J Perinatol 1998 18 311 6 9730205
Pradeepkumar VK, Rajadurai VS, Tan KW. Congenital candidiasis: varied presentations. J Perinatol. 1998;18:311–6.9730205
44. Jain S Gautam V Naseem S Acute-phase proteins: as diagnostic tool J Pharm Bioallied Sci 2011 3 118 27 10.4103/0975-7406.76489 21430962
Jain S, Gautam V, Naseem S. Acute-phase proteins: as diagnostic tool. J Pharm Bioallied Sci. 2011;3:118–27.21430962 10.4103/0975-7406.76489
45. Badr MA Ali YF Albanna EA Beshir MR Amr GE Ventilator associated pneumonia in critically-ill neonates admitted to neonatal intensive care unit, zagazig university hospitals Iran J Pediatr 2011 21 418 24 23056825
Badr MA, Ali YF, Albanna EA, Beshir MR, Amr GE. Ventilator associated pneumonia in critically-ill neonates admitted to neonatal intensive care unit, zagazig university hospitals. Iran J Pediatr. 2011;21:418–24.23056825
46. Katayama Y Minami H Enomoto M Takano T Hayashi S Lee YK Usefulness of Gram staining of tracheal aspirates in initial therapy for ventilator-associated pneumonia in extremely preterm neonates J Perinatol 2010 30 270 4 10.1038/jp.2009.144 19798042
Katayama Y, Minami H, Enomoto M, Takano T, Hayashi S, Lee YK. Usefulness of Gram staining of tracheal aspirates in initial therapy for ventilator-associated pneumonia in extremely preterm neonates. J Perinatol. 2010;30:270–4.19798042 10.1038/jp.2009.144
47. Povoa P Martin-Loeches I Ramirez P Bos LD Esperatti M Silvestre J Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study Ann Intensive Care 2016 6 32 10.1186/s13613-016-0134-8 27076187
Povoa P, Martin-Loeches I, Ramirez P, Bos LD, Esperatti M, Silvestre J, et al. Biomarker kinetics in the prediction of VAP diagnosis: results from the BioVAP study. Ann Intensive Care. 2016;6:32.27076187 10.1186/s13613-016-0134-8
48. Fattah MA Omer AF Asaif S Manlulu R Karar T Ahmed A Utility of cytokine, adhesion molecule and acute phase proteins in early diagnosis of neonatal sepsis J Nat Sci Biol Med 2017 8 32 9 10.4103/0976-9668.198362 28250672
Fattah MA, Omer AF, Asaif S, Manlulu R, Karar T, Ahmed A, et al. Utility of cytokine, adhesion molecule and acute phase proteins in early diagnosis of neonatal sepsis. J Nat Sci Biol Med. 2017;8:32–9.28250672 10.4103/0976-9668.198362
49. Brown JVE Meader N Wright K Cleminson J McGuire W Assessment of C-reactive protein diagnostic test accuracy for late-onset infection in newborn infants: a systematic review and meta-analysis JAMA Pediatr 2020 174 260 8 10.1001/jamapediatrics.2019.5669 32011640
Brown JVE, Meader N, Wright K, Cleminson J, McGuire W. Assessment of C-reactive protein diagnostic test accuracy for late-onset infection in newborn infants: a systematic review and meta-analysis. JAMA Pediatr. 2020;174:260–8.32011640 10.1001/jamapediatrics.2019.5669
50. Chesney RW McCarron DM Haddad JG Hawker CD DiBella FP Chesney PJ Pathogenic mechanisms of the hypocalcemia of the staphylococcal toxic-shock syndrome J Lab Clin Med 1983 101 576 85 6687604
Chesney RW, McCarron DM, Haddad JG, Hawker CD, DiBella FP, Chesney PJ, et al. Pathogenic mechanisms of the hypocalcemia of the staphylococcal toxic-shock syndrome. J Lab Clin Med. 1983;101:576–85.6687604
51. Downes KJ, Fitzgerald JC, Weiss SL. Utility of procalcitonin as a biomarker for sepsis in children. J Clin Microbiol. 2020;58:e01851–19.
52. McWilliam S Riordan A How to use: C-reactive protein Arch Dis Child Educ Pr Ed 2010 95 55 8 10.1136/adc.2009.174367
McWilliam S, Riordan A. How to use: C-reactive protein. Arch Dis Child Educ Pr Ed. 2010;95:55–8.10.1136/adc.2009.174367
53. Zhao X Xu L Yang Z Sun B Wang Y Li G Significance of sTREM-1 in early prediction of ventilator-associated pneumonia in neonates: a single-center, prospective, observational study BMC Infect Dis 2020 20 542 10.1186/s12879-020-05196-z 32711473
Zhao X, Xu L, Yang Z, Sun B, Wang Y, Li G, et al. Significance of sTREM-1 in early prediction of ventilator-associated pneumonia in neonates: a single-center, prospective, observational study. BMC Infect Dis. 2020;20:542.32711473 10.1186/s12879-020-05196-z
54. Nandan D Nimesh M Kumar S Manik L Sudarshan J Duggal N Serum procalcitonin as an early inflammatory marker in pediatric ventilator-associated pneumonia: A prospective observational study J Pediatr Crit Care 2021 8 229 33 10.4103/jpcc.jpcc_55_21
Nandan D, Nimesh M, Kumar S, Manik L, Sudarshan J, Duggal N. Serum procalcitonin as an early inflammatory marker in pediatric ventilator-associated pneumonia: A prospective observational study. J Pediatr Crit Care. 2021;8:229–33.10.4103/jpcc.jpcc_55_21
55. Eschborn S Weitkamp JH Procalcitonin versus C-reactive protein: review of kinetics and performance for diagnosis of neonatal sepsis J Perinatol 2019 39 893 903 10.1038/s41372-019-0363-4 30926891
Eschborn S, Weitkamp JH. Procalcitonin versus C-reactive protein: review of kinetics and performance for diagnosis of neonatal sepsis. J Perinatol. 2019;39:893–903.30926891 10.1038/s41372-019-0363-4
56. Yaegashi Y Shirakawa K Sato N Suzuki Y Kojika M Imai S Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis J Infect Chemother 2005 11 234 8 10.1007/s10156-005-0400-4 16258819
Yaegashi Y, Shirakawa K, Sato N, Suzuki Y, Kojika M, Imai S, et al. Evaluation of a newly identified soluble CD14 subtype as a marker for sepsis. J Infect Chemother. 2005;11:234–8.16258819 10.1007/s10156-005-0400-4
57. Poggi C Lucenteforte E Petri D De Masi S Dani C Presepsin for the diagnosis of neonatal early-onset sepsis: a systematic review and meta-analysis JAMA Pediatr 2022 176 750 8 10.1001/jamapediatrics.2022.1647 35639395
Poggi C, Lucenteforte E, Petri D, De Masi S, Dani C. Presepsin for the diagnosis of neonatal early-onset sepsis: a systematic review and meta-analysis. JAMA Pediatr. 2022;176:750–8.35639395 10.1001/jamapediatrics.2022.1647
58. Savic D Simovic A Markovic S Kostic G Vuletic B Radivojevic S The role of presepsin obtained from tracheal aspirates in the diagnosis of early onset pneumonia in intubated newborns Indian J Pediatr 2018 85 968 73 10.1007/s12098-018-2676-2 29654571
Savic D, Simovic A, Markovic S, Kostic G, Vuletic B, Radivojevic S, et al. The role of presepsin obtained from tracheal aspirates in the diagnosis of early onset pneumonia in intubated newborns. Indian J Pediatr. 2018;85:968–73.29654571 10.1007/s12098-018-2676-2
59. Tusor N De Cunto A Basma Y Klein JL Meau-Petit V Ventilator-associated pneumonia in neonates: the role of point of care lung ultrasound Eur J Pediatr 2021 180 137 46 10.1007/s00431-020-03710-8 32592026
Tusor N, De Cunto A, Basma Y, Klein JL, Meau-Petit V. Ventilator-associated pneumonia in neonates: the role of point of care lung ultrasound. Eur J Pediatr. 2021;180:137–46.32592026 10.1007/s00431-020-03710-8
60. Raycheva R, Rangelova V, Kevorkyan A. Cost analysis for patients with ventilator-associated pneumonia in the neonatal intensive care unit. Healthcare (Basel). 2022;10:980.
61. Dell’Orto V Raschetti R Centorrino R Montane A Tissieres P Yousef N Short- and long-term respiratory outcomes in neonates with ventilator-associated pneumonia Pediatr Pulmonol 2019 54 1982 8 10.1002/ppul.24487 31456358
Dell’Orto V, Raschetti R, Centorrino R, Montane A, Tissieres P, Yousef N, et al. Short- and long-term respiratory outcomes in neonates with ventilator-associated pneumonia. Pediatr Pulmonol. 2019;54:1982–8.31456358 10.1002/ppul.24487
62. Wang HC, Liao CC, Chu SM, Lai MY, Huang HR, Chiang MC, et al. Impacts of multidrug-resistant pathogens and inappropriate initial antibiotic therapy on the outcomes of neonates with ventilator-associated pneumonia. Antibiotics (Basel). 2020;9:760.
63. Korang SK Safi S Gluud C Lausten-Thomsen U Jakobsen JC Antibiotic regimens for neonatal sepsis - a protocol for a systematic review with meta-analysis Syst Rev 2019 8 306 10.1186/s13643-019-1207-1 31805993
Korang SK, Safi S, Gluud C, Lausten-Thomsen U, Jakobsen JC. Antibiotic regimens for neonatal sepsis - a protocol for a systematic review with meta-analysis. Syst Rev. 2019;8:306.31805993 10.1186/s13643-019-1207-1
64. Nakwan N Wannaro J Thongmak T Pornladnum P Saksawad R Nakwan N Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report Pediatr Pulmonol 2011 46 60 6 10.1002/ppul.21324 20812247
Nakwan N, Wannaro J, Thongmak T, Pornladnum P, Saksawad R, Nakwan N, et al. Safety in treatment of ventilator-associated pneumonia due to extensive drug-resistant Acinetobacter baumannii with aerosolized colistin in neonates: a preliminary report. Pediatr Pulmonol. 2011;46:60–6.20812247 10.1002/ppul.21324
65. Hussain K Salat MS Ambreen G Mughal A Idrees S Sohail M Intravenous vs intravenous plus aerosolized colistin for treatment of ventilator-associated pneumonia - a matched case-control study in neonates Expert Opin Drug Saf 2020 19 1641 9 10.1080/14740338.2020.1819980 32892635
Hussain K, Salat MS, Ambreen G, Mughal A, Idrees S, Sohail M, et al. Intravenous vs intravenous plus aerosolized colistin for treatment of ventilator-associated pneumonia - a matched case-control study in neonates. Expert Opin Drug Saf. 2020;19:1641–9.32892635 10.1080/14740338.2020.1819980
66. Mathur NB Murugesan A Comparison of four days versus seven days duration of antibiotic therapy for neonatal pneumonia: a randomized controlled trial Indian J Pediatr 2018 85 963 7 10.1007/s12098-018-2708-y 29781043
Mathur NB, Murugesan A. Comparison of four days versus seven days duration of antibiotic therapy for neonatal pneumonia: a randomized controlled trial. Indian J Pediatr. 2018;85:963–7.29781043 10.1007/s12098-018-2708-y
67. Engle WD Jackson GL Sendelbach D Ford D Olesen B Burton KM Neonatal pneumonia: comparison of 4 vs 7 days of antibiotic therapy in term and near-term infants J Perinatol 2000 20 421 6 10.1038/sj.jp.7200416 11076325
Engle WD, Jackson GL, Sendelbach D, Ford D, Olesen B, Burton KM, et al. Neonatal pneumonia: comparison of 4 vs 7 days of antibiotic therapy in term and near-term infants. J Perinatol. 2000;20:421–6.11076325 10.1038/sj.jp.7200416
68. Lewald ZS Prusakov P Magers JK Kielt MJ de Alba Romero C White NO Short-course antibiotic therapy for pneumonia in the neonatal intensive care unit J Perinatol 2023 43 1145 51 10.1038/s41372-023-01720-6 37438484
Lewald ZS, Prusakov P, Magers JK, Kielt MJ, de Alba Romero C, White NO, et al. Short-course antibiotic therapy for pneumonia in the neonatal intensive care unit. J Perinatol. 2023;43:1145–51.37438484 10.1038/s41372-023-01720-6
69. Tablan Anderson OC Besser LJ Bridges R Hajjeh C Cdc R Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee MMWR Recomm Rep. 2004 53 1 36 15048056
Tablan, Anderson OC, Besser LJ, Bridges R, Hajjeh C, Cdc R, et al. Guidelines for preventing health-care-associated pneumonia, 2003: recommendations of CDC and the Healthcare Infection Control Practices Advisory Committee. MMWR Recomm Rep. 2004;53:1–36.15048056
70. Rogers E Alderdice F McCall E Jenkins J Craig S Reducing nosocomial infections in neonatal intensive care J Matern Fetal Neonatal Med 2010 23 1039 46 10.3109/14767050903387029 20718580
Rogers E, Alderdice F, McCall E, Jenkins J, Craig S. Reducing nosocomial infections in neonatal intensive care. J Matern Fetal Neonatal Med. 2010;23:1039–46.20718580 10.3109/14767050903387029
71. Won SP Chou HC Hsieh WS Chen CY Huang SM Tsou KI Handwashing program for the prevention of nosocomial infections in a neonatal intensive care unit Infect Control Hosp Epidemiol 2004 25 742 6 10.1086/502470 15484798
Won SP, Chou HC, Hsieh WS, Chen CY, Huang SM, Tsou KI, et al. Handwashing program for the prevention of nosocomial infections in a neonatal intensive care unit. Infect Control Hosp Epidemiol. 2004;25:742–6.15484798 10.1086/502470
72. Cordero L Sananes M Ayers LW Comparison of a closed (Trach Care MAC) with an open endotracheal suction system in small premature infants J Perinatol 2000 20 151 6 10.1038/sj.jp.7200330 10802838
Cordero L, Sananes M, Ayers LW. Comparison of a closed (Trach Care MAC) with an open endotracheal suction system in small premature infants. J Perinatol. 2000;20:151–6.10802838 10.1038/sj.jp.7200330
73. Azab SF Sherbiny HS Saleh SH Elsaeed WF Elshafiey MM Siam AG Reducing ventilator-associated pneumonia in neonatal intensive care unit using “VAP prevention Bundle”: a cohort study BMC Infect Dis 2015 15 314 10.1186/s12879-015-1062-1 26246314
Azab SF, Sherbiny HS, Saleh SH, Elsaeed WF, Elshafiey MM, Siam AG, et al. Reducing ventilator-associated pneumonia in neonatal intensive care unit using “VAP prevention Bundle”: a cohort study. BMC Infect Dis. 2015;15:314.26246314 10.1186/s12879-015-1062-1
74. Jacobs Pepin B Lesslie D Berg W Spaulding AB Pokora T ZAP-VAP: A Quality Improvement Initiative to Decrease Ventilator-Associated Pneumonia in the Neonatal Intensive Care Unit, 2012-2016 Adv Neonatal Care 2019 19 253 61 10.1097/ANC.0000000000000635 31246616
Jacobs Pepin B, Lesslie D, Berg W, Spaulding AB, Pokora T. ZAP-VAP: A Quality Improvement Initiative to Decrease Ventilator-Associated Pneumonia in the Neonatal Intensive Care Unit, 2012-2016. Adv Neonatal Care. 2019;19:253–61.31246616 10.1097/ANC.0000000000000635
75. Ceballos K Waterman K Hulett T Makic MB Nurse-driven quality improvement interventions to reduce hospital-acquired infection in the NICU Adv Neonatal Care 2013 13 154 63 10.1097/ANC.0b013e318285fe70 23722485
Ceballos K, Waterman K, Hulett T, Makic MB. Nurse-driven quality improvement interventions to reduce hospital-acquired infection in the NICU. Adv Neonatal Care. 2013;13:154–63.23722485 10.1097/ANC.0b013e318285fe70
76. Pinilla-Gonzalez A Solaz-Garcia A Parra-Llorca A Lara-Canton I Gimeno A Izquierdo I Preventive bundle approach decreases the incidence of ventilator-associated pneumonia in newborn infants J Perinatol 2021 41 1467 73 10.1038/s41372-021-01086-7 34035449
Pinilla-Gonzalez A, Solaz-Garcia A, Parra-Llorca A, Lara-Canton I, Gimeno A, Izquierdo I, et al. Preventive bundle approach decreases the incidence of ventilator-associated pneumonia in newborn infants. J Perinatol. 2021;41:1467–73.34035449 10.1038/s41372-021-01086-7
77. Bagucka B De Schepper J Peelman M Van de Maele K Vandenplas Y Acid gastro-esophageal reflux in the 10 degrees-reversed-Trendelenburg-position in supine sleeping infants Acta Paediatr Taiwan 1999 40 298 301 10910536
Bagucka B, De Schepper J, Peelman M, Van de Maele K, Vandenplas Y. Acid gastro-esophageal reflux in the 10 degrees-reversed-Trendelenburg-position in supine sleeping infants. Acta Paediatr Taiwan. 1999;40:298–301.10910536
78. Goodstein MH, Stewart DL, Keels EL, Moon RY, Committee On F, Newborn TFOSIDS. Transition to a Safe Home Sleep Environment for the NICU Patient. Pediatrics. 2021;148:e2021052045.
79. Slaughter JL Stenger MR Reagan PB Jadcherla SR Neonatal histamine-2 receptor antagonist and proton pump inhibitor treatment at United States children’s hospitals J Pediatr 2016 174 63 70.e3 10.1016/j.jpeds.2016.03.059 27131401
Slaughter JL, Stenger MR, Reagan PB, Jadcherla SR. Neonatal histamine-2 receptor antagonist and proton pump inhibitor treatment at United States children’s hospitals. J Pediatr. 2016;174:63–70.e3.27131401 10.1016/j.jpeds.2016.03.059
80. Reinhart RM McClary JD Zhang M Marasch JL Hibbs AM Nock ML Reducing antacid use in a level IV NICU: A QI project to reduce morbidity Pediatr Qual Saf 2020 5 e303 10.1097/pq9.0000000000000303 32607459
Reinhart RM, McClary JD, Zhang M, Marasch JL, Hibbs AM, Nock ML. Reducing antacid use in a level IV NICU: A QI project to reduce morbidity. Pediatr Qual Saf. 2020;5:e303.32607459 10.1097/pq9.0000000000000303
81. Machado MC Cheng D Tarquinio KM Webster TJ Nanotechnology: pediatric applications Pediatr Res 2010 67 500 4 10.1203/PDR.0b013e3181d68e78 20139795
Machado MC, Cheng D, Tarquinio KM, Webster TJ. Nanotechnology: pediatric applications. Pediatr Res. 2010;67:500–4.20139795 10.1203/PDR.0b013e3181d68e78
82. Sun YC Wang CY Wang HL Yuan Y Lu JH Zhong L Probiotic in the prevention of ventilator-associated pneumonia in critically ill patients: evidence from meta-analysis and trial sequential analysis of randomized clinical trials BMC Pulm Med 2022 22 168 10.1186/s12890-022-01965-5 35484547
Sun YC, Wang CY, Wang HL, Yuan Y, Lu JH, Zhong L. Probiotic in the prevention of ventilator-associated pneumonia in critically ill patients: evidence from meta-analysis and trial sequential analysis of randomized clinical trials. BMC Pulm Med. 2022;22:168.35484547 10.1186/s12890-022-01965-5
83. Ryan RM Wilding GE Wynn RJ Welliver RC Holm BA Leach CL Effect of enhanced ultraviolet germicidal irradiation in the heating ventilation and air conditioning system on ventilator-associated pneumonia in a neonatal intensive care unit J Perinatol 2011 31 607 14 10.1038/jp.2011.16 21436785
Ryan RM, Wilding GE, Wynn RJ, Welliver RC, Holm BA, Leach CL. Effect of enhanced ultraviolet germicidal irradiation in the heating ventilation and air conditioning system on ventilator-associated pneumonia in a neonatal intensive care unit. J Perinatol. 2011;31:607–14.21436785 10.1038/jp.2011.16
84. Ma A Yang J Li Y Zhang X Kang Y Oropharyngeal colostrum therapy reduces the incidence of ventilator-associated pneumonia in very low birth weight infants: a systematic review and meta-analysis Pediatr Res 2021 89 54 62 10.1038/s41390-020-0854-1 32225172
Ma A, Yang J, Li Y, Zhang X, Kang Y. Oropharyngeal colostrum therapy reduces the incidence of ventilator-associated pneumonia in very low birth weight infants: a systematic review and meta-analysis. Pediatr Res. 2021;89:54–62.32225172 10.1038/s41390-020-0854-1
85. Ezzeldin Z Mansi Y Gaber M Zakaria R Fawzy R Mohamed MA Nebulized hypertonic saline to prevent ventilator associated pneumonia in premature infants, a randomized trial J Matern Fetal Neonatal Med 2018 31 2947 52 10.1080/14767058.2017.1359826 28738709
Ezzeldin Z, Mansi Y, Gaber M, Zakaria R, Fawzy R, Mohamed MA. Nebulized hypertonic saline to prevent ventilator associated pneumonia in premature infants, a randomized trial. J Matern Fetal Neonatal Med. 2018;31:2947–52.28738709 10.1080/14767058.2017.1359826
86. Adivitiya, Kaushik MS, Chakraborty S, Veleri S, Kateriya S. Mucociliary Respiratory Epithelium Integrity in Molecular Defense and Susceptibility to Pulmonary Viral Infections. Biology (Basel). 2021;10:95.
87. Kumar V Pulmonary Innate Immune Response Determines the Outcome of Inflammation During Pneumonia and Sepsis-Associated Acute Lung Injury Front Immunol 2020 11 1722 10.3389/fimmu.2020.01722 32849610
Kumar V. Pulmonary Innate Immune Response Determines the Outcome of Inflammation During Pneumonia and Sepsis-Associated Acute Lung Injury. Front Immunol. 2020;11:1722.32849610 10.3389/fimmu.2020.01722
